197 related articles for article (PubMed ID: 32458089)
21. Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole.
Segregur D; Barker R; Mann J; Moir A; Karlsson EM; Turner DB; Arora S; Dressman J
Eur J Pharm Sci; 2021 May; 160():105750. PubMed ID: 33581261
[TBL] [Abstract][Full Text] [Related]
22. Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.
Koziolek M; Carrière F; Porter CJH
Pharm Res; 2018 Feb; 35(3):55. PubMed ID: 29423732
[TBL] [Abstract][Full Text] [Related]
23. Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
Lloyd RS; Hingle MI; Bloomer JC; Charles SJ; Butler JM; Paul A; Zhu X; Miller B; D'Amico D; Donald A; Tal-Singer R; Ambery C
Pharm Res; 2020 Oct; 37(12):233. PubMed ID: 33123802
[TBL] [Abstract][Full Text] [Related]
24. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
[TBL] [Abstract][Full Text] [Related]
25. Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Meneses-Lorente G; Guerini E; Mercier F; Parrott N; Kowalski K; Chow-Maneval E; Buchheit V; Bergthold G; Fox E; Phipps A; Djebli N
Cancer Chemother Pharmacol; 2023 Mar; 91(3):239-246. PubMed ID: 36884068
[TBL] [Abstract][Full Text] [Related]
26. Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin.
Parrott N; Hainzl D; Scheubel E; Krimmer S; Boetsch C; Guerini E; Martin-Facklam M
AAPS J; 2014 Sep; 16(5):1077-84. PubMed ID: 24970349
[TBL] [Abstract][Full Text] [Related]
27. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
28. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
30. Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug-Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models.
Wagner C; Kesisoglou F; Pepin XJH; Parrott N; Emami Riedmaier A
AAPS J; 2021 Jun; 23(4):85. PubMed ID: 34142242
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
[TBL] [Abstract][Full Text] [Related]
32. Can PBPK Modeling Streamline Food Effect Assessments?
Kesisoglou F
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S98-S104. PubMed ID: 33205433
[TBL] [Abstract][Full Text] [Related]
33. In-vitro-in-silico investigation of the negative food effect of zolpidem when administered as immediate-release tablets.
Paraiso RLM; Watanabe A; Andreas CJ; Turner D; Zane P; Dressman J
J Pharm Pharmacol; 2019 Nov; 71(11):1663-1676. PubMed ID: 31566757
[TBL] [Abstract][Full Text] [Related]
34. Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254).
Stamatopoulos K; Ferrini P; Nguyen D; Zhang Y; Butler JM; Hall J; Mistry N
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839843
[TBL] [Abstract][Full Text] [Related]
35. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
Radwan A; Jayyousi R; Shraim N; Zaid AN
Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
[TBL] [Abstract][Full Text] [Related]
37. Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging.
Belubbi T; Bassani D; Stillhart C; Parrott N
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678820
[TBL] [Abstract][Full Text] [Related]
38. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
[TBL] [Abstract][Full Text] [Related]
39. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
